AU2018243753A1 - Replacement of cytotoxic preconditioning before cellular immunotherapy - Google Patents

Replacement of cytotoxic preconditioning before cellular immunotherapy Download PDF

Info

Publication number
AU2018243753A1
AU2018243753A1 AU2018243753A AU2018243753A AU2018243753A1 AU 2018243753 A1 AU2018243753 A1 AU 2018243753A1 AU 2018243753 A AU2018243753 A AU 2018243753A AU 2018243753 A AU2018243753 A AU 2018243753A AU 2018243753 A1 AU2018243753 A1 AU 2018243753A1
Authority
AU
Australia
Prior art keywords
cells
cell
dose
dexamethasone
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2018243753A
Other languages
English (en)
Inventor
Theresa Ann DEISHER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AVM Biotechnology LLC
Original Assignee
AVM Biotechnology LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AVM Biotechnology LLC filed Critical AVM Biotechnology LLC
Publication of AU2018243753A1 publication Critical patent/AU2018243753A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicinal Preparation (AREA)
AU2018243753A 2017-04-01 2018-03-30 Replacement of cytotoxic preconditioning before cellular immunotherapy Abandoned AU2018243753A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762480414P 2017-04-01 2017-04-01
US62/480,414 2017-04-01
US201862613697P 2018-01-04 2018-01-04
US62/613,697 2018-01-04
US201862624454P 2018-01-31 2018-01-31
US62/624,454 2018-01-31
PCT/US2018/025517 WO2018183927A1 (en) 2017-04-01 2018-03-30 Replacement of cytotoxic preconditioning before cellular immunotherapy

Publications (1)

Publication Number Publication Date
AU2018243753A1 true AU2018243753A1 (en) 2019-10-10

Family

ID=62111173

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018243753A Abandoned AU2018243753A1 (en) 2017-04-01 2018-03-30 Replacement of cytotoxic preconditioning before cellular immunotherapy

Country Status (13)

Country Link
US (2) US11219628B2 (https=)
EP (1) EP3490605B1 (https=)
JP (2) JP6748221B2 (https=)
KR (1) KR102509006B1 (https=)
CN (1) CN110475571B (https=)
AU (1) AU2018243753A1 (https=)
BR (1) BR112019020214A2 (https=)
CA (1) CA3054443A1 (https=)
ES (1) ES2954311T3 (https=)
IL (1) IL269209B2 (https=)
MX (1) MX2019011679A (https=)
SG (1) SG11201907744QA (https=)
WO (1) WO2018183927A1 (https=)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10426740B1 (en) 2010-08-18 2019-10-01 Avm Biotechnology, Llc Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues
WO2025019711A2 (en) * 2023-07-19 2025-01-23 Dermtech, Inc. Predicting therapeutic response based on biomarker signatures
EP3490605B1 (en) 2017-04-01 2023-06-07 AVM Biotechnology, LLC Replacement of cytotoxic preconditioning before cellular immunotherapy
EP4732889A2 (en) 2017-06-07 2026-04-29 Supira Medical, Inc. Intravascular fluid movement devices, systems, and methods of use
JP7319266B2 (ja) 2017-11-13 2023-08-01 シファメド・ホールディングス・エルエルシー 血管内流体移動デバイス、システム、および使用方法
EP4085965A1 (en) 2018-02-01 2022-11-09 Shifamed Holdings, LLC Intravascular blood pumps and methods of use and manufacture
US11459393B2 (en) 2018-04-17 2022-10-04 Celldex Therapeutics, Inc. Anti-CD27 and anti-PD-L1 antibodies and bispecific constructs
US12161857B2 (en) 2018-07-31 2024-12-10 Shifamed Holdings, Llc Intravascular blood pumps and methods of use
EP3488851A1 (en) 2018-10-03 2019-05-29 AVM Biotechnology, LLC Immunoablative therapies
EP3632446B3 (en) 2018-10-03 2024-01-24 AVM Biotechnology, LLC Immunoablative therapies
WO2020073047A1 (en) 2018-10-05 2020-04-09 Shifamed Holdings, Llc Intravascular blood pumps and methods of use
JP7337060B2 (ja) 2018-11-14 2023-09-01 エーブイエム・バイオテクノロジー・エルエルシー 安定なグルココルチコイド製剤
AU2019379815A1 (en) * 2018-11-16 2021-06-03 Rapa Therapeutics, Llc Methods for treating cancer with manufactured T cells
US20220016168A1 (en) * 2018-12-11 2022-01-20 Celldex Therapeutics, Inc. Methods of using cd27 antibodies as conditioning treatment for adoptive cell therapy
KR102840400B1 (ko) 2018-12-12 2025-08-04 카이트 파마 인코포레이티드 키메라 항원 수용체 및 car-t 세포 및 사용 방법
EP3996797A4 (en) 2019-07-12 2023-08-02 Shifamed Holdings, LLC INTRAVASCULAR BLOOD PUMPS AND METHOD OF USE AND METHOD OF MAKING
US11654275B2 (en) 2019-07-22 2023-05-23 Shifamed Holdings, Llc Intravascular blood pumps with struts and methods of use and manufacture
EP4010046A4 (en) 2019-08-07 2023-08-30 Calomeni, Michael Catheter blood pumps and collapsible pump housings
US12102815B2 (en) 2019-09-25 2024-10-01 Shifamed Holdings, Llc Catheter blood pumps and collapsible pump housings
US12121713B2 (en) 2019-09-25 2024-10-22 Shifamed Holdings, Llc Catheter blood pumps and collapsible blood conduits
EP4034192B1 (en) 2019-09-25 2025-12-24 Supira Medical, Inc. Intravascular blood pump systems and methods of use and control thereof
IL292665B2 (en) * 2019-11-06 2026-02-01 Kite Pharma Inc Chimeric antigen receptor T cell therapy
EP4072650A4 (en) 2019-12-11 2024-01-10 Shifamed Holdings, LLC Descending aorta and vena cava blood pumps
WO2021127503A1 (en) 2019-12-19 2021-06-24 Shifamed Holdings, Llc Intravascular blood pumps, motors, and fluid control
CN113189340A (zh) * 2020-01-14 2021-07-30 中国医学科学院基础医学研究所 细胞焦亡通路在细胞治疗中的用途
US12252701B2 (en) 2020-02-20 2025-03-18 Kite Pharma, Inc. Chimeric antigen receptor T cell therapy
CN115516085A (zh) * 2020-02-28 2022-12-23 Avm生物技术有限责任公司 淋巴细胞群体以及用于产生所述淋巴细胞群体的方法
CN111443210B (zh) * 2020-04-10 2023-09-22 青海大学附属医院 泡型包虫病早期诊疗生物标志物及其应用
JP2023531122A (ja) * 2020-04-10 2023-07-21 ノース カロライナ ステート ユニバーシティ 材料足場を使用した哺乳類細胞の増強されたウイルス形質導入
JP2023524434A (ja) 2020-04-29 2023-06-12 エーブイエム・バイオテクノロジー・エルエルシー 新規療法
CA3180424A1 (en) * 2020-06-01 2021-12-09 Theresa Deisher Methods of treatment using icam-modulating agents
CN113797313A (zh) * 2020-06-11 2021-12-17 华北制药集团新药研究开发有限责任公司 卡非佐米作为冠状病毒广谱抑制剂的新用途
US20230270783A1 (en) * 2020-09-01 2023-08-31 The National Institute for Biotechnology in the Negev Ltd. Immune system restoration by cell therapy
CN113322233A (zh) * 2021-04-19 2021-08-31 格源致善(上海)生物科技有限公司 一种改进的基于新生抗原反应性t细胞的制备方法及应用
AU2022261141A1 (en) * 2021-04-23 2023-11-30 Myeloid Therapeutics, Inc. Compositions and methods for conditioning patients for cell therapy
CN113480614B (zh) * 2021-08-13 2023-01-10 中国人民解放军总医院 一类靶向pd-l1的超高亲和力小蛋白及用途
CA3229529A1 (en) 2021-09-01 2023-03-09 Avm Biotechnology, Llc Lymphocyte population and methods for producing same
CN114031678A (zh) * 2021-12-08 2022-02-11 中国科学院新疆理化技术研究所 一种条斑钳蝎毒素多肽组分的制备方法及其应用
CN114767828A (zh) * 2022-04-25 2022-07-22 中国人民解放军海军军医大学 伊沙佐米在制备抗蜱传脑炎病毒、西尼罗病毒、黄热病毒和基孔肯雅热病毒感染药物中的应用
CN115785203B (zh) * 2022-06-10 2024-03-12 河北博海生物工程开发有限公司 肺癌特异性分子靶标10及其用途
CN116606352B (zh) * 2023-07-14 2023-09-29 诺赛联合(北京)生物医学科技有限公司 一种抗菌修复功能的组合物凝胶在妇科疾病中的应用
KR20250139235A (ko) 2025-07-15 2025-09-23 김종구 V-aemi 기반 인공지능 감정 음악 창작 시스템 및 그 방법

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728388A (en) 1989-10-03 1998-03-17 Terman; David S. Method of cancer treatment
GB9323199D0 (en) 1993-11-10 1994-01-05 Falkenberg J H F Leukaemia treatment
ES2285720T3 (es) 1997-12-16 2007-11-16 University Of Zurich Metodo de fabricacion de productos terapeuticos pra la encefalopatia espongiforme transmisible, productos sanguineos y tejidos no infecciosos y metodos para su obtencion.
US6406699B1 (en) 1999-10-05 2002-06-18 Gary W. Wood Composition and method of cancer antigen immunotherapy
US20030099621A1 (en) * 2001-11-29 2003-05-29 Robert Chow Stem cell screening and transplantation therapy for HIV infection
IL146970A0 (en) 2001-12-06 2002-08-14 Yeda Res & Dev Migration of haematopoietic stem cells and progenitor cells to the liver
IL164079A0 (en) 2002-03-15 2005-12-18 Us Dept Veterans Affairs Methods and compositions using cellular asialodeterminants and glycoconjugates for targeting cells to tissues and organs
CN102342938B (zh) 2002-05-17 2014-08-20 细胞基因公司 用于治疗和控制实体瘤的方法及组合物
GB0310593D0 (en) 2003-05-08 2003-06-11 Leuven K U Res & Dev Peptidic prodrugs
US20040247574A1 (en) 2003-05-27 2004-12-09 Christopherson Kent W. Methods for enhancing stem cell engraftment during transplantation
EP1835924B1 (en) 2004-12-23 2013-08-21 Ethicon, Incorporated Treatment of parkinson's disease and related disorders using postpartum derived cells
CA2606081C (en) * 2005-04-26 2013-09-17 Markus M. Heiss Combination of the application of antibodies for immunostimulation together with glucocorticoids
EP1907425B1 (en) 2005-07-22 2014-01-08 Y's Therapeutics Co., Ltd. Anti-cd26 antibodies and methods of use thereof
US8278104B2 (en) 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
GB0700058D0 (en) 2007-01-03 2007-02-07 Scancell Aps Anti-tumor vaccine based on normal cells
US20100247491A1 (en) 2007-02-01 2010-09-30 Christof Westenfelder Potentiation of Stem Cell Homing and Treatment of Organ Dysfunction or Organ Failure
CA2725198A1 (en) 2008-05-23 2009-11-26 Argos Therapeutics, Inc. Novel soluble cd83 polypeptides, formulations and methods of use
US20090299269A1 (en) 2008-05-29 2009-12-03 John Foley Vascular stimulation to aid intravascular cell replacement therapy
WO2009152186A1 (en) 2008-06-09 2009-12-17 American Stem Cell, Inc. Methods for enhancing cell therapy efficacy including treatment with cd26 peptidase inhibitors
ES2627043T3 (es) 2008-06-09 2017-07-26 Targazyme, Inc. Aumento de la eficacia de la terapia celular incluyendo tratamiento con alfa 1-3 fucoslitransferasa
US20100055107A1 (en) * 2008-07-31 2010-03-04 Defu Zeng Methods for preventing hematological malignancies and graft versus host disease by anti-cd3 preconditioning
US10426740B1 (en) * 2010-08-18 2019-10-01 Avm Biotechnology, Llc Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues
NZ607906A (en) * 2010-08-18 2015-11-27 Theresa Deisher Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US9402865B2 (en) 2011-01-18 2016-08-02 The Trustees Of The University Of Pennsylvania Compositions and methods for treating cancer
EP2532740A1 (en) 2011-06-11 2012-12-12 Michael Schmück Antigen-specific CD4+ and CD8+ central-memory T cell preparations for adoptive T cell therapy
WO2013040557A2 (en) 2011-09-16 2013-03-21 The Trustees Of The University Of Pennsylvania Rna engineered t cells for the treatment of cancer
WO2014055657A1 (en) 2012-10-05 2014-04-10 The Trustees Of The University Of Pennsylvania Use of a trans-signaling approach in chimeric antigen receptors
AU2015244039B2 (en) * 2014-04-07 2021-10-21 Novartis Ag Treatment of cancer using anti-CD19 chimeric antigen receptor
ES2869972T3 (es) * 2015-01-26 2021-10-26 Cellectis Sistemas de receptores de antígenos quiméricos dirigidos por mAb para clasificar/agotar células inmunitarias genomanipuladas
IL295224B2 (en) * 2015-05-28 2025-07-01 Kite Pharma Inc Methods of conditioning patients for t cell therapy
AU2017368248A1 (en) * 2016-11-30 2019-06-06 Intrexon Corporation Steroid administration and immunotherapy
EP3490605B1 (en) 2017-04-01 2023-06-07 AVM Biotechnology, LLC Replacement of cytotoxic preconditioning before cellular immunotherapy
EP3488851A1 (en) * 2018-10-03 2019-05-29 AVM Biotechnology, LLC Immunoablative therapies

Also Published As

Publication number Publication date
US11219628B2 (en) 2022-01-11
JP2020114837A (ja) 2020-07-30
MX2019011679A (es) 2019-11-01
IL269209B2 (en) 2023-11-01
JP6748221B2 (ja) 2020-08-26
ES2954311T3 (es) 2023-11-21
SG11201907744QA (en) 2019-09-27
EP3490605A1 (en) 2019-06-05
CA3054443A1 (en) 2018-10-14
KR102509006B1 (ko) 2023-03-13
EP3490605C0 (en) 2023-06-07
JP2019515888A (ja) 2019-06-13
EP3490605B1 (en) 2023-06-07
US20220160729A1 (en) 2022-05-26
JP7162632B2 (ja) 2022-10-28
WO2018183927A1 (en) 2018-10-04
IL269209A (en) 2019-11-28
IL269209B1 (en) 2023-07-01
BR112019020214A2 (pt) 2020-04-22
KR20190130624A (ko) 2019-11-22
US20180296572A1 (en) 2018-10-18
CN110475571B (zh) 2023-04-04
CN110475571A (zh) 2019-11-19

Similar Documents

Publication Publication Date Title
US11219628B2 (en) Replacement of cytotoxic preconditioning before cellular immunotherapy
JP7695882B2 (ja) 養子細胞療法を用いた処置のための方法
Swart et al. Combination approaches with immune-checkpoint blockade in cancer therapy
WO2021053667A2 (en) Combination cancer therapy and cytokine control therapy for cancer treatment
JP7671125B2 (ja) 免疫除去療法
CN104853776A (zh) 免疫应答的增强
US20170058026A1 (en) Methods for modulating immune responses during chronic immune conditions by targeting il-27 induced pathways
AU2020350221A1 (en) Combination cancer therapy and cytokine control therapy for cancer treatment
JP2025521543A (ja) Ｃｄ１９標的ｃａｒ ｔ細胞のセカンドライン治療のための処置方法
JP2024536217A (ja) 操作されたｎｋ細胞及びその使用
US20240000883A1 (en) Method of sensitizing cancers to immunotherapy using immunomodulatory agents
HK40008076A (en) Replacement of cytotoxic preconditioning before cellular immunotherapy
HK40008076B (en) Replacement of cytotoxic preconditioning before cellular immunotherapy
EA043393B1 (ru) Замена цитотоксического предварительного кондиционирования перед клеточной иммунотерапией
JP2023526228A (ja) 膠芽腫を処置するための方法
TW202224703A (zh) 治療癌症之方法、治療劑及用途
HK40088121A (zh) 用於治疗胶质母细胞瘤的方法
HK40026712A (en) Methods of administering chimeric antigen receptor immunotherapy

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period